{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Angiogenesis > RegorafenibCAS：755037-03-7
Molecular Formula：C21H15ClF4N4O3
Molecular Weight：482.82
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：HPLC≥98%
Appearance：White to light red Solid
Qty：
Size：
| CAS | 755037-03-7 |
| Name | Regorafenib |
| Molecular Formula | C21H15ClF4N4O3 |
| Molecular Weight | 482.82 |
| Solubility | Soluble in DMSO ≥5mg/mL |
| Purity | HPLC≥98% |
| Appearance | White to light red Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 815-051-1 |
| MDL | MFCD16038047 |
| SMILES | O=C(NC1=CC=C(C(C(F)(F)F)=C1)Cl)NC2=CC=C(OC3=CC(C(NC)=O)=NC=C3)C=C2F |
| Target Point | VEGFR |
| Passage | Angiogenesis;Protein Tyrosine Kinase/RTK |
| Background | Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor that inhibits VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1. |
| Biological Activity | Regorafenib (BAY 73-4506) 是一种多靶点受体酪氨酸激酶抑制剂，抑制VEGFR1/2/3，PDGFRβ，Kit，RET 和 Raf-1 的 IC50 分别为13/4.2/46，22，7，1.5 和2.5 nM。[1-5] |
| IC50 | VEGFR2:4.2nM;PDGFRβ:22nM;Raf-1:2.5nM [1-5] |
| Data Literature Source | [1]. Wilhelm SM，et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic，stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer，2011，129(1)，245-255. [2]. Heng DY，et al. Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol，2010，2(1)，39-49. [3]. Carr BI，et al. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition，quiescence，and recovery. J Cell Physiol，2013，228(2)，292-297. [4]. Wagner J，et al. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms. J Exp Clin Cancer Res. 2018 Jan 22;37(1):11. [5]. Matsuoka K，et al. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells. Int J Mol Sci. 2018 Sep 25;19(10). pii: E2915. |
| Unit | Bottle |
| Specification | 10mg 10mM*1mL in DMSO 50mg 100mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
